Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
Is Most-Watched Stock GSK PLC Sponsored ADR (GSK) Worth Betting on Now?
01:00pm, Thursday, 08'th Sep 2022 Zacks Investment Research
Glaxo (GSK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is Most-Watched Stock GSK PLC Sponsored ADR (GSK) Worth Betting on Now?
10:32am, Thursday, 08'th Sep 2022
Glaxo (GSK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
GSK plc (GSK) Citi's 17th Annual BioPharma Conference Earnings Call Transcript
01:47am, Thursday, 08'th Sep 2022
GSK plc (NYSE:GSK ) Citi's 17th Annual BioPharma Conference September 7, 2022 1:50 PM ET Company Participants Roger Connor - President, Global Vaccines & Global Health Phil Dormitzer - Senior Vice Pre
GSK's NDA for Daprodustat to be Reviewed by an FDA Panel
03:40pm, Wednesday, 07'th Sep 2022 Zacks Investment Research
GSK's regulatory applications for daprodustat are based on data from the ASCEND phase III program, consisting of five studies.
Making Healthcare More Efficient Could Benefit Select ETFs
11:40am, Wednesday, 07'th Sep 2022
The U.S. doesn't have nationalized healthcare comparable to some other developed countries, and it is home to one of the most lumbering, inefficient healthcare systems. It would be to the benefit of h
GSK targets further cut by investment banks over potential Zantac legal risks
08:16am, Wednesday, 07'th Sep 2022
Two major investment banks cut their target prices for GSK PLC (LSE:GSK, NYSE:GSK) as analysts drilled down into the potential fallout from the Zantac litigation and saw the potential for total liabil
Gilead (GILD) Announces Positive New Data on Breast Cancer Drug
02:16pm, Tuesday, 06'th Sep 2022 Zacks Investment Research
Gilead (GILD) breast cancer drug Trodelvy shows efficacy across HER2-low and IHC0 status in pre-treated metastatic breast cancer patients.
2 Top Trends to Invest $2,000 in Ahead of the Crowd
02:45pm, Monday, 05'th Sep 2022 The Motley Fool
These two trends on the frontier of medicine could present lucrative opportunities for investment.
GSK (GSK) Gains As Market Dips: What You Should Know
09:45pm, Friday, 02'nd Sep 2022 Zacks Investment Research
GSK (GSK) closed at $31.85 in the latest trading session, marking a +0.5% move from the prior day.
Rolls-Royce, GSK, Tesla, Cineworld and Revolution Beauty top most-bought shares in August
02:45am, Friday, 02'nd Sep 2022
August's most popular shares for retail investors were dominated by apparent bargain hunting, with Rolls-Royce Holdings PLC (LSE:RR.), GSK PLC (LSE:GSK, NYSE:GSK) and Vodafone Group PLC (LSE:VOD) snap
This Overlooked Danger Could Tank Big Pharma Stocks
06:13pm, Thursday, 01'st Sep 2022
It started out relatively small, or as small as a recall of one of the first drugs to top $1 billion in annual sales can be. In September 2019, individual companies began recalling popular heartburn m
AstraZeneca wins injunction preventing former executive from joining GSK
10:55am, Thursday, 01'st Sep 2022
AstraZeneca PLC (LSE:AZN) has succeeded in stopping a former senior executive from joining rival GSK PLC (LSE:GSK, NYSE:GSK) via an injunction granted by a High Court judge. Having recently left A
Gilead (GILD) Outpaces Industry in Six Months: What Lies Ahead?
03:51pm, Tuesday, 30'th Aug 2022 Zacks Investment Research
Gilead (GILD) gains on the back of its strong HIV franchise and promising oncology business, which should propel growth further.
Pfizer (PFE) RSV Vaccine Found Effective in Older Adults
10:52am, Friday, 26'th Aug 2022 Zacks Investment Research
Based on the positive data from the phase III study on its RSV vaccine candidate, Pfizer plans to file a biologics license application (BLA) to the FDA in fall 2022.
3 Dependable Stocks With Dividend Yields Above 5%
02:53pm, Wednesday, 24'th Aug 2022 The Motley Fool
These three will pay you well while you wait for their shares to rebound.
